Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2
Objective Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ)...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 4; pp. 808 - 813 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.04.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 2326-5191 2326-5205 2326-5205 |
DOI | 10.1002/art.40014 |
Cover
Summary: | Objective
Imbalanced cytokine production by T cells characterizes both patients with systemic lupus erythematosus (SLE) and lupus‐prone mice and contributes to immune dysregulation. This study was undertaken to further investigate in detail the production of interleukin‐2 (IL‐2), interferon‐γ (IFNγ), IL‐4, and IL‐17A by CD4+ cell subsets in healthy subjects and patients with SLE, and the signaling response of CD4+ T cells in response to exogenous IL‐2.
Methods
Cytokine production by differentiated subsets of CD4+ T cells was assessed by intracellular staining following stimulation with phorbol myristate acetate and ionomycin and by enzyme‐linked immunosorbent assay after anti‐CD3/anti‐CD28 stimulation. The IL‐2 signaling pathway was examined by assessing JAK‐3/STAT‐5 phosphorylation. Cell proliferation in response to IL‐2 was examined by carboxyfluorescein succinimidyl ester dilution.
Results
Production of IL‐2 was defective primarily among naive CD4+ T cells, whereas the production of IFNγ, IL‐4, and IL‐17A was not significantly different between patients with SLE and healthy subjects. JAK‐3/STAT‐5 phosphorylation and proliferation of CD4+ T cells from SLE patients in response to exogenous IL‐2 were impaired compared to cells from healthy subjects.
Conclusion
These data suggest that altered IL‐2 production, as well as impaired IL‐2–mediated signaling and proliferative responses, characterize SLE CD4+ T cells. Our data demonstrate the need for caution in designing IL‐2 treatment trials for patients with SLE. Approaches to restore CD4+ T cell sensitivity to IL‐2 should be considered. |
---|---|
Bibliography: | Drs. Comte and Karampetsou contributed equally to this work. Supported by the NIH (grants P01‐AI‐065687, R01‐AI‐42269, and R37‐AI‐49954 to Dr. Tsokos) and the SICPA Foundation (grant to Dr. Comte). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2326-5191 2326-5205 2326-5205 |
DOI: | 10.1002/art.40014 |